<DOC>
	<DOCNO>NCT00709267</DOCNO>
	<brief_summary>The purpose study determine bioavailability orally administer folic acid compare i.v . administer folic acid , use sample collect validate analytical method estimation folic acid plasma red blood cell ( RBCs ) .</brief_summary>
	<brief_title>Bioavailability Study Folic Acid Healthy Women</brief_title>
	<detailed_description>Few formal pharmacokinetic study conduct folic acid determine absolute bioavailability , pharmacokinetic profile , intra- intersubject variability . Moreover , analytical work complete academic setting , Good Laboratory Practice ( GLP ) -validated assay method develop . This randomize ( study drug assign chance ) , open-label , 3-way crossover , single-center trial , consist prerandomization phase , open-label treatment phase ( 3 single dos separate washout 7 day ) , posttreatment phase . Healthy volunteer randomly assign 1 6 treatment sequence ( 2 healthy volunteer per sequence ) . All healthy volunteer receive single dose folic acid treatment period ( 400-mcg oral solution , 400-mcg i.v . infusion , 1-mg oral tablet ) . Blood sample pharmacokinetic analysis collect specified time follow dose . Blood sample measurement red cell folate collect dose Day 1 Period 1 . For period , healthy volunteer confine study unit even Day 1 completion Day 2 assessment ( 24-hour pharmacokinetic blood sample collection ) . End-of-study assessment take place Day 17 time early withdrawal . Safety evaluate base monitoring adverse event , vital sign measurement , physical examination , clinical laboratory test . Heart rate blood pressure measure screening , first day treatment period ( Days 1 , 8 , 15 ) , study completion ( Day 17 ) early withdrawal ; body temperature measure screening . A physical examination perform screen study completion ( Day 17 ) early withdrawal . Blood sample serum chemistry hematology random urine sample urinalysis take start study , Days -21 -2 , end study ( Day 17 early termination ) . All subject receive single dose folic acid treatment period ( 400-mcg oral solution , 400-mcg i.v . infusion , 1-mg oral tablet ) , separate washout 7 day .</detailed_description>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Healthy Nonpregnant Nonlactating Nonsmoking woman With history regular menstrual cycle Weighing least 110 pound Having body mass index 18 28 kg/m2 And hematocrit least 36 % Known history vitamin B12 deficiency current need vitamin B12 injection Elevated blood pressure ( BP ) ( i.e. , sit systolic BP &gt; 140 mm mercury [ Hg ] and/or diastolic BP &gt; 90 mm Hg ) Had test positive human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( antiHCV ) Recent history ( within 12 month prior first admission visit ) alcohol substance abuse test positive drug abuse , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , methadone , opiates , tricyclic antidepressant agent Used barbiturate , antiepileptic , rifampin , griseofulvin , St. John 's Wort hepatic enzyme induce drug within 30 day randomization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Folic Acid</keyword>
	<keyword>Chemistry , Analytical</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Biological Availability</keyword>
	<keyword>Safety</keyword>
</DOC>